You can buy or sell APOP and other stocks, options, ETFs, and crypto commission-free!
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. Read More The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. Cellect Biotechnology was founded by Kasbian Nuriel Chirich, Shai Yarkoni and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.
Kfar Saba, Jerusalem
52 Week High
52 Week Low
PR NewswireMar 18
Cellect Biotechnology Reports Fourth Quarter and Full Year 2018 Results and Recent Corporate Progress
TEL AVIV, Israel, March 18, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of a novel stem cell production technology, today announced operating and financial results for the fourth quarter and full year ended December 31, 2018, as well as recent corporate progress. "We made progress in 2018 as we overcame the short-term setback of patient recruitment in our trial in Israel and moved closer to the initiation of our U.S. clinical efforts," commented Dr. Shai Yarkoni, Chief Execu...